The biologic activity of the mTOR inhibitor temsirolimus is further confirmed by the upregulation of nestin seen in the patient's IGFR/mTOR resistant tumor, since temsirolimus down-modulates EWS-FLI1, which would be expected to upregulate nestin [26], [27] (Figure 7). Here, MTOR is linked to neoplasm.